Sun Pharmaceuticals Industries Ltd (SUNPHARMA)

Generic Drugmakers Benefit from Sales of Revlimid Versions - 10 May, 2024

Sun Pharmaceuticals Industries Ltd, along with other generic drugmakers such as Dr Reddy's and Zydus Lifesciences, have benefitted from rising sales of their own generic versions of Revlimid in the US.

Sun Pharma Acquires Valstar S.A. - 06 May, 2024

Sun Pharmaceuticals Industries Ltd has entered into an agreement to acquire a 100% stake in Valstar S.A. for $31 million.

Indian Pharma Companies Expected to Benefit from Patent Cliff and Short Supply of Key Drugs - 02 May, 2024

Unmesh Sharma, Head of Institutional Equities at HDFC Securities, expects Indian pharma companies like Sun Pharma, Dr Reddys Labs, Cipla, and Aurobindo Pharma to benefit from the patent cliff and short supply of key drugs due to the closure of facilities of several manufacturers. This creates incremental revenue opportunities for Indian players.

Aurobindo, Sun Pharma and Gland Pharma to Benefit from US Drug Shortages - 30 Apr, 2024

Due to elevated levels of active drug shortages in the United States, Aurobindo Pharma, Sun Pharmaceutical Industries, and Gland Pharma are projected to make significant strides in the US market. Sun Pharma has 31 products under shortage.

Sun Pharma Receives Tax Demand of Over Rs 1.11 Crore - 29 Apr, 2024

Sun Pharmaceutical Industries Ltd has received a tax demand of over Rs 1.11 crore from authorities due to disallowed input tax credit on account of inadmissible transitional credit. The company stated that there is no material impact on financial, operation or other activities.

Sun Pharmaceuticals Industries Ltd Market Cap Drops by 3.4% - 25 Apr, 2024

Last week, Sun Pharmaceuticals Industries Ltd saw a 3.4% decrease in its market cap, affecting private companies and institutions who own a significant portion of the company. Insider ownership is positive, but the general public holds only an 18% stake.

Motilal Oswal Reiterates Buy Rating for Sun Pharma - 24 Apr, 2024

Motilal Oswal has reiterated its Buy rating for Sun Pharmaceuticals Industries Ltd. with a target price of Rs 1,870 per share. The report highlights the company's specialty drug pipeline and expects an overall R&D expenditure increase by 33% YoY in FY24.

Sun Pharma Monitoring Situation in Israel - 20 Apr, 2024

Sun Pharmaceuticals Industries Ltd is monitoring the situation in Israel through its subsidiary, Taro Pharmaceutical, and taking necessary steps to ensure employee safety.

Sun Pharma's Taro Pharmaceutical may face supply chain issues - 19 Apr, 2024

Sun Pharma's subsidiary, Taro Pharmaceutical, based in Israel, could experience supply chain problems. Companies like Sun Pharma Lupin, Torrent, and Divis Labs are likely to be affected due to their significant presence in the MENA region.

Sun Pharma Faces Regulatory Challenges - 18 Apr, 2024

Sun Pharmaceuticals Industries Ltd faces regulatory challenges after its Dadra facility was classified as Official Action Indicated (OAI) by the US FDA. Analysts and investors hold a bearish view on the stock, which may fall up to Rs 1,330 apiece in the rest of the month.

Delhi High Court Upholds Order Against Glenmark Pharmaceuticals - 17 Apr, 2024

The Delhi High Court has upheld its order restraining Glenmark Pharmaceuticals from manufacturing, selling or advertising its asthma drug under the mark Indamet or any other deceptively similar mark to Sun Pharma's Istamet XR CP until the case is disposed of.

Sun Pharma Shares Decline on Regulatory Concerns - 15 Apr, 2024

Sun Pharma's shares decline due to USFDA issuing an OAI tag to its Mumbai unit, which may impact new launches. Analysts expect limited earnings impact but see a regulatory overhang for the drugmaker.

Sun Pharma Shares Fall After US FDA Classification - 12 Apr, 2024

Sun Pharmaceutical Industries Ltd faced a significant setback when its Dadra facility was classified as Official Action Indicated by the US Food and Drug Administration, leading to a 4% decline in share prices. The company will cooperate with regulators to achieve compliance status.